Phase IIb, GS-6624 in subjects with primary sclerosing cholangitis

• Research type

  Research Study

• Full title

  A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)

• IRAS ID

  115804

• Contact name

  Roger W G Chapman

• Contact email

  roger.chapman@ndm.ox.ac.uk

• Sponsor organisation

  Gilead Sciences Inc

• Eudract number

  2012-002473-61

• Clinicaltrials.gov Identifier

  NCT01672853

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  13/SC/0174

• Date of REC Opinion

  17 May 2013

• REC opinion

  Further Information Favourable Opinion